Anti-human cd69 antibody, and use thereof for medical purposes

Abstract

The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

1 - 19 . (canceled) 
     
     
         20 . A method of preventing or treating an allergic or inflammatory disease, the method comprising administering an antibody comprising a light chain variable region and a heavy chain variable region to a subject expressing human CD69,
 wherein the antibody binds to an epitope of the human CD69, and   wherein the epitope consists of 12 or less amino acid residues and comprises the amino acid sequence of SEQ ID NO: 33.   
     
     
         21 . The method according to  claim 20 , wherein the epitope is a continuous partial sequence of the amino acid sequence of SEQ ID NO: 30 
     
     
         22 . The method according to  claim 20 , wherein the epitope consists of the amino acid sequence of SEQ ID NO: 35 or 36. 
     
     
         23 . The method according to  claim 20 , wherein the antibody cross-reacts with mouse CD69. 
     
     
         24 . The method according to  claim 20 , wherein the subject has allergic inflammation. 
     
     
         25 . The method according to  claim 20 ,
 wherein the light chain variable region comprises: CDR1 comprising the amino acid sequence of SEQ ID NO: 7; CDR2 comprising the amino acid sequence of SEQ ID NO: 8; and CDR3 comprising the amino acid sequence of SEQ ID NO: 9, 19 or 20, and   wherein the heavy chain variable region comprises: CDR1 comprising the amino acid sequence of SEQ ID NO: 10; CDR2 comprising the amino acid sequence of SEQ ID NO: 11; and CDR3 comprising the amino acid sequence of SEQ ID NO: 12.   
     
     
         26 . The method according to  claim 20 ,
 wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 23, 27 or 28, and   wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 24.   
     
     
         27 . The method according to  claim 20 ,
 wherein the light chain variable region comprises: CDR1 comprising the amino acid sequence of SEQ ID NO: 7; CDR2 comprising the amino acid sequence of SEQ ID NO: 8; and CDR3 comprising the amino acid sequence of SEQ ID NO: 9, 19 or 20,   wherein the heavy chain variable region comprises: CDR1 comprising the amino acid sequence of SEQ ID NO: 10; CDR2 comprising the amino acid sequence of SEQ ID NO: 11; and CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and   wherein 1 to 3 amino acid residues are substituted, deleted, inserted, and/or added in at least one amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 7-12, 19 and 20.   
     
     
         28 . The method according to  claim 27 , wherein 1 or 2 amino acid residues are substituted, deleted, inserted, and/or added in at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 7-12, 19 and 20. 
     
     
         29 . The method according to  claim 27 , wherein 1 amino acid residue is substituted, deleted, inserted, or added in at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 7-12, 19 and 20.